| HOME | MEETINGS | MEMBERSHIP | EXHIBITORS | AWARDS | INFO | NEWS | ABOUT US | CONTACT | SIGN IN |
ensuring knowledge, enhancing quality
A 'not-for-profit' organisation,
run for pharmaceutical analysts by pharmaceutical analysts
run for pharmaceutical analysts by pharmaceutical analysts
| HOME | MEETINGS | MEMBERSHIP | EXHIBITORS | AWARDS | INFO | NEWS | ABOUT US | CONTACT | SIGN IN |
NEXT EVENT: Thursday 19th September 2019 - Advancements in pharmaceutical QC testing: dissolution and QbD testing... 
JPAG - serving its members since 1970
JPAG plans and delivers events that address all aspects of pharmaceutical analysis and related facets of medicine control & registration.
NEXT EVENTS:
LAST EVENT:
JPAG plans and delivers events that address all aspects of pharmaceutical analysis and related facets of medicine control & registration.
NEXT EVENTS:
Thursday 19th September 2019
Advancements in pharmaceutical QC testing: dissolution and QbD testing
Royal Society of Chemistry, London
This one-day symposium will address issues and challenges associated with both dissolution and analytical QbD from a pharmacopoeial perspective. The first session will include overviews on the current/future state of dissolution testing from the regulators (MHRA), the British Pharmacopoeia (BP) and industry. It will be followed by a panel discussion. The role of statistical modelling in predicting dissolution issues will be discussed and finally the key question of how can we introduce meaningful pharmacopoeial dissolution specifications for modified release products, will be discussed.
The second session will focus on measurement uncertainty and analytical QbD from the regulators (MHRA), the British Pharmacopoeia (BP) and industry perspectives. This will be followed by a panel discussion.
This symposium will provide an excellent opportunity for dialogue, discussion and debate with speakers - several of whom have been very actively involved in shaping the various guidances - and the peer group in an open forum. Delegates will be able to understand, interpret and translate into day-to-day practice how the various guidelines are being interpreted by regulators and pharmacopoeias.
An excellent opportunity to learn from expert speakers involved in the interpretation and application of these key topics.
Confirmed Speakers:
Dr Himal Makwana, BP
Dr James Mann, AZ
Dr Karin Boon, MHRA
Dr Gary Scrivens, Pfizer
Dr Himal Makwana, BP
Prof Clive Wilson, Strathclyde
Dr Steve Maddocks, BP
Ms Elena Razzano, MHRA
Dr Phil Borman, GSK
DETAILS AND REGISTRATION
Advancements in pharmaceutical QC testing: dissolution and QbD testing
Royal Society of Chemistry, London
This one-day symposium will address issues and challenges associated with both dissolution and analytical QbD from a pharmacopoeial perspective. The first session will include overviews on the current/future state of dissolution testing from the regulators (MHRA), the British Pharmacopoeia (BP) and industry. It will be followed by a panel discussion. The role of statistical modelling in predicting dissolution issues will be discussed and finally the key question of how can we introduce meaningful pharmacopoeial dissolution specifications for modified release products, will be discussed.
The second session will focus on measurement uncertainty and analytical QbD from the regulators (MHRA), the British Pharmacopoeia (BP) and industry perspectives. This will be followed by a panel discussion.
This symposium will provide an excellent opportunity for dialogue, discussion and debate with speakers - several of whom have been very actively involved in shaping the various guidances - and the peer group in an open forum. Delegates will be able to understand, interpret and translate into day-to-day practice how the various guidelines are being interpreted by regulators and pharmacopoeias.
An excellent opportunity to learn from expert speakers involved in the interpretation and application of these key topics.
Confirmed Speakers:
Dr Himal Makwana, BP
Dr James Mann, AZ
Dr Karin Boon, MHRA
Dr Gary Scrivens, Pfizer
Dr Himal Makwana, BP
Prof Clive Wilson, Strathclyde
Dr Steve Maddocks, BP
Ms Elena Razzano, MHRA
Dr Phil Borman, GSK
DETAILS AND REGISTRATION
Thursday 10th October 2019
Mutagenic Impurities
Royal Society of Chemistry, London
This one-day symposium will address issues and challenges associated with mutagenic impurities. It will provide an excellent opportunity for dialogue, discussion and debate with speakers - several of whom have been very actively involved in shaping the guidance - and the peer group in an open forum.
Delegates will be able to understand, interpret and translate into day-to-day practice the guidance on how the guidelines are being interpreted by regulators and pharmacopoeias. An overview of the latest approaches to purging (i.e. ICH M7 option 4) from the Mirabilis consortium, several analytical case studies showing state-of-the-art approaches to the analysis of MIs, a case study showing how the mutagenic risk assessment (MRA) is translated into CTD format for subsequent regulatory filing. There will also be a timely update on the Valsartan contamination issue: what happened, why it happened and how it is being controlled.
An excellent opportunity to learn from expert speakers involved in the interpretation and application of these key topics.
Confirmed speakers:
Dr Andy Teasdale, AZ
Dr Richard Jones, GSK
Dr Mike Urquhart, GSK
DETAILS AND REGISTRATION
Mutagenic Impurities
Royal Society of Chemistry, London
This one-day symposium will address issues and challenges associated with mutagenic impurities. It will provide an excellent opportunity for dialogue, discussion and debate with speakers - several of whom have been very actively involved in shaping the guidance - and the peer group in an open forum.
Delegates will be able to understand, interpret and translate into day-to-day practice the guidance on how the guidelines are being interpreted by regulators and pharmacopoeias. An overview of the latest approaches to purging (i.e. ICH M7 option 4) from the Mirabilis consortium, several analytical case studies showing state-of-the-art approaches to the analysis of MIs, a case study showing how the mutagenic risk assessment (MRA) is translated into CTD format for subsequent regulatory filing. There will also be a timely update on the Valsartan contamination issue: what happened, why it happened and how it is being controlled.
An excellent opportunity to learn from expert speakers involved in the interpretation and application of these key topics.
Confirmed speakers:
Dr Andy Teasdale, AZ
Dr Richard Jones, GSK
Dr Mike Urquhart, GSK
DETAILS AND REGISTRATION
Tuesday 26th November 2019
The pharmaceutical analysis research awards and careers symposium 2019
Royal Society of Chemistry, London
JPAG presents the third pharmaceutical analysis symposium for postgraduate students and early career stage scientists, including those in industry. This will provide the opportunity for delegates to showcase their work and network with peers, academics and industrial scientists through oral and poster presentations. There will be a £1,000 first prize and £250 second prize for the best oral presentations as well as £200 first prize and two runner-up prizes of £100 for the best posters. Authors who submit an abstract that is accepted for presentation (oral or poster) will receive a complimentary registration.
The closing date for submission of abstracts is Saturday 31 August.
In addition, there will be a Networking and Careers Fair, open to undergraduate and postgraduate students well as early career stage scientists, with the opportunity to meet with big industry pharma and other key contacts and take advantage of the great networking opportunities.
This could be the event to provide a step-change to your professional career. Perhaps your future employer will be here.
There will be a presentation from the Royal Society of Chemistry's Careers Specialists Julie Franklin and Sarah Salter on 'Job hunting in the pharmaceutical industry'. They will also conduct a 'CV Surgery' for RSC members; these are one-to-one discussions for members to find out how to present a good CV. So be sure to bring your CV along!
Registration will open at 8:30am for a 9am start, and the day will end with a Careers and Networking wine reception starting at 6pm.
Speakers:
Prof Abdul Basit - UCL
Julie Franklin - Royal Society of Chemistry
Jonelle Harvey - Royal Society of Chemistry
Prof Michael Heinrich - UCL
Sarah Salter - Royal Society of Chemistry
DETAILS AND REGISTRATION
The pharmaceutical analysis research awards and careers symposium 2019
Royal Society of Chemistry, London
JPAG presents the third pharmaceutical analysis symposium for postgraduate students and early career stage scientists, including those in industry. This will provide the opportunity for delegates to showcase their work and network with peers, academics and industrial scientists through oral and poster presentations. There will be a £1,000 first prize and £250 second prize for the best oral presentations as well as £200 first prize and two runner-up prizes of £100 for the best posters. Authors who submit an abstract that is accepted for presentation (oral or poster) will receive a complimentary registration.
The closing date for submission of abstracts is Saturday 31 August.
In addition, there will be a Networking and Careers Fair, open to undergraduate and postgraduate students well as early career stage scientists, with the opportunity to meet with big industry pharma and other key contacts and take advantage of the great networking opportunities.
This could be the event to provide a step-change to your professional career. Perhaps your future employer will be here.
There will be a presentation from the Royal Society of Chemistry's Careers Specialists Julie Franklin and Sarah Salter on 'Job hunting in the pharmaceutical industry'. They will also conduct a 'CV Surgery' for RSC members; these are one-to-one discussions for members to find out how to present a good CV. So be sure to bring your CV along!
Registration will open at 8:30am for a 9am start, and the day will end with a Careers and Networking wine reception starting at 6pm.
Speakers:
Prof Abdul Basit - UCL
Julie Franklin - Royal Society of Chemistry
Jonelle Harvey - Royal Society of Chemistry
Prof Michael Heinrich - UCL
Sarah Salter - Royal Society of Chemistry
DETAILS AND REGISTRATION
COLLABORATIVE EVENT: Wednesday 11th September 2019
10th APS International PharmSci conference 2019
University of Greenwich (Maritime Campus)
DETAILS AND REGISTRATION
10th APS International PharmSci conference 2019
University of Greenwich (Maritime Campus)
DETAILS AND REGISTRATION
LAST EVENT:
Thursday 9th May 2019
Assuring the quality of medicines III; aseptic products
Royal Society of Chemistry, London
The quality of Aseptic products is the most critical challenge in the pharmaceutical industry. It covers those medicinal products that cannot be terminally sterilised, the majority of new injectable IMPs and all gene therapy and ATMPs. In addition, 2019 is a vitally important year as the revised Annex 1 becomes globally implemented and provides a host of challenges for the industry trying to implement it. JPAG has been able to bring together a unique and almost unparalleled group of speakers in a programme that tries to cover the hottest topics in this field.
There will be adequate time after each presentation to discuss case studies and practical implications.
DETAILS
Assuring the quality of medicines III; aseptic products
Royal Society of Chemistry, London
The quality of Aseptic products is the most critical challenge in the pharmaceutical industry. It covers those medicinal products that cannot be terminally sterilised, the majority of new injectable IMPs and all gene therapy and ATMPs. In addition, 2019 is a vitally important year as the revised Annex 1 becomes globally implemented and provides a host of challenges for the industry trying to implement it. JPAG has been able to bring together a unique and almost unparalleled group of speakers in a programme that tries to cover the hottest topics in this field.
There will be adequate time after each presentation to discuss case studies and practical implications.
DETAILS
Our only sponsors are our parent professional bodies:
Delegates of any JPAG symposia can access the speakers presentations.
Just SIGN IN, go to RESOURCES and look in MY PAST MEETINGS.
Just SIGN IN, go to RESOURCES and look in MY PAST MEETINGS.
Missed the meeting?
You can access a short report of recent meetings!
Just go to the MEETINGS page, go to PAST EVENTS. Then select the DETAILS for the meeting that interests you.
And do be sure to check the list of upcoming meetings so that you don't miss the next one!
You can access a short report of recent meetings!
Just go to the MEETINGS page, go to PAST EVENTS. Then select the DETAILS for the meeting that interests you.
And do be sure to check the list of upcoming meetings so that you don't miss the next one!
European Pharmaceutical Review
JPAG members can receive a free hard copy subscription to EPR
click here
JPAG members can receive a free hard copy subscription to EPR
click here
TESTIMONIALS:
Very enjoyable and thought-provoking day; going away with plenty of notes and specific items for discussion.
Excellent meeting, challenging and thought provoking. The organisation was excellent, thanks to all the efforts that JPAG team have made.
I have not attended a bad JPAG meeting yet. They are really good value for money and I really love to get the presentations as PDFs
LATEST NEWS:
Mutagenic impurities: a done deal? Part 2
Here is another article in the series reproduced with permission from the European Pharmaceutical Review. It is entitled "Mutagenic impurities: a done deal?” written by Dr Dave Elder, Past-Chairman of the JPAG Committee More...
Wednesday 27th February 2019
Here is another article in the series reproduced with permission from the European Pharmaceutical Review. It is entitled "Mutagenic impurities: a done deal?” written by Dr Dave Elder, Past-Chairman of the JPAG Committee More...
Wednesday 27th February 2019
Brexit and balance
Here is another article in the series reproduced with permission from the European Pharmaceutical Review. It is entitled "Brexit and balance” written by Dr Dave Elder, Past-Chairman of the JPAG Committee More...
Thursday 31st January 2019
Here is another article in the series reproduced with permission from the European Pharmaceutical Review. It is entitled "Brexit and balance” written by Dr Dave Elder, Past-Chairman of the JPAG Committee More...
Thursday 31st January 2019
Mutagenic impurities: a done deal?
Here is another article in the series reproduced with permission from the European Pharmaceutical Review. It is entitled "Mutagenic impurities: a done deal?” written by Dr Dave Elder, Past-Chairman of the JPAG Committee More...
Thursday 31st January 2019
Here is another article in the series reproduced with permission from the European Pharmaceutical Review. It is entitled "Mutagenic impurities: a done deal?” written by Dr Dave Elder, Past-Chairman of the JPAG Committee More...
Thursday 31st January 2019
COOKIES AND PERSONAL DATA:
This site does not use cookies.
However, it does securely hold details for those who register an account.
This information is only used by JPAG as described in the Privacy Statement (see link on footer below).
Follow us:
| Call us: | CONTACT US | Follow us: | | Terms and Conditions Privacy Statement |
| © Joint Pharmaceutical Analysis Group 2019 Website by Delta Consultancy Services |
|